Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine...
applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(95)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Dec 15, 2023 10:32am
Directors compensation
We pay them why? Worst bunch of management on the NASDAQ. This should be performance based compensation and not receiving high salaries and crazy stock options for being greedy.
(44)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Post by
FarmerBetsy
on Dec 09, 2023 5:56pm
Preferred Shares Sept 22, 2023 Sec
Preferred Shares and Series 1 Preferred Shares The Preferred Shares of the Company may be issued in one or more series and the directors are authorized to fix the number of Preferred Shares in
...more
Silvercorp to Acquire Adventus, Creating a Diversified Mining Company
posted May 02, 2024 9:00am by
Adventus Mining Corp.
-
|
Under the terms of the Arrangement Agreement, each holder of the common shares of Adventus will receive 0.1015 of one Silvercorp common share in exchange for each Adventus Share at the effective time of the Transaction. The Exchange Ratio implies consideration of C$0.50 per Adventus Share ...read more
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Dec 09, 2023 11:53am
RE:Converted the 70,000,000 preferred shares
70,000,000 preferred shares converted into 1,166,667 preferred shares to comport with previous 60:1 r/s. https://www.promisneurosciences.com/investors/sec-filings/content/0001558370-23-019700
...more
(44)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Post by
FarmerBetsy
on Dec 09, 2023 8:16am
Converted the 70,000,000 preferred shares
The Boston Group.
(95)
•••
goldtech
X
View Profile
View Bullboard History
Comment by
goldtech
on Dec 07, 2023 8:51pm
RE:Pre consolidation
Yes you are correct and this board lets the corrupt group dictate terms of financing and how and when they will do it. Most pathetic Biotech on the Nasadaq . No CEO or board member has ever thought
...more
(45)
•••
Alex1726
X
View Profile
View Bullboard History
Post by
Alex1726
on Dec 07, 2023 6:23pm
Pre consolidation
On a pre cosidelation basis this stock worth $0.026 cdn cents. $1.16 US DIVIDED BY 60 X 1.36 That's a real mess AND GUESS WHAT they probably grab millions as pay check for 2023.
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Dec 07, 2023 11:58am
RE:RE:RE:RE:RE:Any hope?
Yes, the final proof will be in the clinic. Hopefully the Phase 1b data has low or no ARIA-E. That would be huge. The hypothesis is already supported by the clinical data from competitors to
...more
(97)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Dec 07, 2023 6:57am
RE:RE:RE:RE:Any hope?
My point is that PMN310 shows its selective binding to oligomers, not monomers pre-clinical still needs to be proven in humans. We're not there yet. And even if it does will it be more beneficial
...more
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Dec 06, 2023 3:30pm
RE:RE:RE:Any hope?
If you review the AAIC poster, available at: https://d1io3yog0oux5.cloudfront.net/_f444b23cf4fc6297ab91dfdf03041ca0/promisneurosciences/db/1004/8793/pdf/2023+AAIC+PMN310+poster.pdf Figures 4
...more
(97)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Dec 06, 2023 2:30pm
RE:RE:Any hope?
"I remain hopeful about the technical (scientific) outlook for PMN310. Based on pre-clinical data, it looks like it should be an effective and more selective product than anything out there
...more
(7)
•••
Ardbeg
X
View Profile
View Bullboard History
Comment by
Ardbeg
on Dec 06, 2023 2:24pm
RE:RE:Any hope?
Thanks for taking the time to respond
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Dec 06, 2023 8:55am
RE:Any hope?
This is my opinion and not investment advice (I'm down 60% after averaging down a bit). I remain hopeful about the technical (scientific) outlook for PMN310. Based on pre-clinical data, it looks
...more
(7)
•••
Ardbeg
X
View Profile
View Bullboard History
Post by
Ardbeg
on Dec 05, 2023 11:30pm
Any hope?
I'm down 88% :(
(45)
•••
Alex1726
X
View Profile
View Bullboard History
Comment by
Alex1726
on Nov 23, 2023 6:56pm
RE:Elliot, Ouch to the many haters could be a hate crime !
The real story is not about Promis entering Alzheimer clinical trials that's not going to happen. I said that few years ago , they never intended to conduct any clinical trial , they just thought
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project